BRAF and melanoma: Several studies in patients with brain metastases from BRAF-mutant melanoma showed higher response rates with dabrafenib compared to vemurafenib, suggesting that the former might better penetrate the blood-brain barrier (BBB) with respect to the latter, thanks to its smaller size (13).